A mechanistic study to determine the relevance of Benralizumab targets (eosinophil-numbers and IL5-receptor) in patients with skin disorders. - ROBERTIS (Relevance of Benralizumab targets in skin disorders)

Trial Profile

A mechanistic study to determine the relevance of Benralizumab targets (eosinophil-numbers and IL5-receptor) in patients with skin disorders. - ROBERTIS (Relevance of Benralizumab targets in skin disorders)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Atopic dermatitis; Bullous pemphigoid; Dermatitis herpetiformis; Granuloma annulare; Mycosis fungoides; Prurigo; Urticaria
  • Focus Pharmacodynamics
  • Acronyms ROBERTIS
  • Most Recent Events

    • 13 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top